This study aims to check if a new medicine called ibuzatrelvir is safe and effective for people with COVID-19 who are not in the hospital but are at risk of becoming very sick. Participants, who are 12 years and older, will take either ibuzatrelvir or a placebo (a pill with no medicine) for 5 days. The study will last about 6 months. People can keep taking their regular medicines along with the study. To join, you must have some risk factors like being overweight or having diabetes.

Key Points:

• Study lasts around 6 months.
• Participants take study medicine for 5 days.
• Regular medicines can be continued.

To participate, you cannot need hospital care right away and must not have other severe illnesses. Participants must also be unable or unwilling to take certain other COVID-19 medicines. If you have had a different COVID-19 treatment, a recent vaccine, or if you've been in a similar study before, you may not qualify. This study is for understanding how ibuzatrelvir works in preventing severe COVID-19 in those not hospitalized but at risk.